Prothena Corporation plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Prothena Corporation plc
The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.
The Danish group put the 5-HT6 antagonist on the shelf after three failed late-stage trials but Denovo believes that idalopirdine could still work for a subset of Alzheimer's patients.
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
With post hoc analysis from a 2018 study showing a survival benefit in patients at high risk for early mortality, Prothena negotiated a path forward with the US FDA for approval in AL amyloidosis.
- Large Molecule
- Other Names / Subsidiaries
- Neotope Biosciences Limited